<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241022001409
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241022001409" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Tue, 22 Oct 2024 04:14:11 +0000</lastbuilddate>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Bleeding After Cardiovascular Surgery: A Continuing Problem</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432577/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1324-1326. doi: 10.1161/CIRCULATIONAHA.124.071147. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432577/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39432577</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071147>10.1161/CIRCULATIONAHA.124.071147</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432577</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Frank W Sellke</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Bleeding After Cardiovascular Surgery: A Continuing Problem</dc:title>
<dc:identifier>pmid:39432577</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071147</dc:identifier>
</item>
<item>
<title>Partial Heart Transplantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1313-1314. doi: 10.1161/CIRCULATIONAHA.124.071498. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39432576</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071498>10.1161/CIRCULATIONAHA.124.071498</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432576</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Taufiek K Rajab</dc:creator>
<dc:creator>Alekhya Mitta</dc:creator>
<dc:creator>Brian L Reemtsen</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Partial Heart Transplantation</dc:title>
<dc:identifier>pmid:39432576</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071498</dc:identifier>
</item>
<item>
<title>Evolution of Coronary Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1311-1312. doi: 10.1161/CIRCULATIONAHA.124.070918. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39432575</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070918>10.1161/CIRCULATIONAHA.124.070918</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432575</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Bruce Lytle</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Evolution of Coronary Surgery</dc:title>
<dc:identifier>pmid:39432575</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070918</dc:identifier>
</item>
<item>
<title>Introduction to the 2024 Cardiovascular Surgery-Themed Issue of &lt;em>;Circulation&lt;/em>;</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432574/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1307. doi: 10.1161/CIRCULATIONAHA.124.072090. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432574/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39432574</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072090>10.1161/CIRCULATIONAHA.124.072090</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432574</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marc Ruel</dc:creator>
<dc:creator>James de Lemos</dc:creator>
<dc:creator>Michael Fischbein</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Introduction to the 2024 Cardiovascular Surgery-Themed Issue of &lt;em>;Circulation&lt;/em>;</dc:title>
<dc:identifier>pmid:39432574</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072090</dc:identifier>
</item>
<item>
<title>Against Odds of Prolonged Warm Ischemia: Early Experience With DCD Heart Transplantation After 20-Minute No-Touch Period</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432573/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1391-1393. doi: 10.1161/CIRCULATIONAHA.124.071239. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432573/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39432573</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.071239>10.1161/CIRCULATIONAHA.124.071239</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432573</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gino Gerosa</dc:creator>
<dc:creator>Giovanni Battista Luciani</dc:creator>
<dc:creator>Nicola Pradegan</dc:creator>
<dc:creator>Vincenzo Tarzia</dc:creator>
<dc:creator>Tea Lena</dc:creator>
<dc:creator>Paolo Zanatta</dc:creator>
<dc:creator>Demetrio Pittarello</dc:creator>
<dc:creator>Francesco Onorati</dc:creator>
<dc:creator>Antonella Galeone</dc:creator>
<dc:creator>Leonardo Gottin</dc:creator>
<dc:creator>Massimo Boffini</dc:creator>
<dc:creator>Marinella Zanierato</dc:creator>
<dc:creator>Matteo Marro</dc:creator>
<dc:creator>Sofia Martin Suarez</dc:creator>
<dc:creator>Luca Botta</dc:creator>
<dc:creator>Paola Lilla Della Monica</dc:creator>
<dc:creator>Mariano Feccia</dc:creator>
<dc:creator>Guido Maria Olivieri</dc:creator>
<dc:creator>Amedeo Terzi</dc:creator>
<dc:creator>Alessandra Oliveti</dc:creator>
<dc:creator>Giuseppe Feltrin</dc:creator>
<dc:creator>Massimo Cardillo</dc:creator>
<dc:creator>Claudio Francesco Russo</dc:creator>
<dc:creator>Davide Pacini</dc:creator>
<dc:creator>Mauro Rinaldi</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Against Odds of Prolonged Warm Ischemia: Early Experience With DCD Heart Transplantation After 20-Minute No-Touch Period</dc:title>
<dc:identifier>pmid:39432573</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.071239</dc:identifier>
</item>
<item>
<title>Progressive Understanding of Aortic Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39432572/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 22;150(17):1308-1310. doi: 10.1161/CIRCULATIONAHA.124.070477. Epub 2024 Oct 21.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39432572/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39432572</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070477>10.1161/CIRCULATIONAHA.124.070477</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39432572</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Tara M Mastracci</dc:creator>
<dc:creator>Stéphan Haulon</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Progressive Understanding of Aortic Disease</dc:title>
<dc:identifier>pmid:39432572</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070477</dc:identifier>
</item>
<item>
<title>The Netrod™ six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39431289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae703. doi: 10.1093/eurheartj/ehae703. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39431289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39431289</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae703>10.1093/eurheartj/ehae703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39431289</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yueping Li</dc:creator>
<dc:creator>Fei Gao</dc:creator>
<dc:creator>Changjie Ren</dc:creator>
<dc:creator>Genshan Ma</dc:creator>
<dc:creator>Peili Bu</dc:creator>
<dc:creator>Guosheng Fu</dc:creator>
<dc:creator>Hao Chen</dc:creator>
<dc:creator>Zhanying Han</dc:creator>
<dc:creator>Yan Li</dc:creator>
<dc:creator>Jing Li</dc:creator>
<dc:creator>Xiang Ma</dc:creator>
<dc:creator>Liuyi Hao</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Mao Chen</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:creator>Xuebo Liu</dc:creator>
<dc:creator>Jiangang Jiang</dc:creator>
<dc:creator>Jing Yu</dc:creator>
<dc:creator>Nanfang Li</dc:creator>
<dc:creator>Xueping Ma</dc:creator>
<dc:creator>Bin Yang</dc:creator>
<dc:creator>Hongliang Cong</dc:creator>
<dc:creator>Xuekun Wang</dc:creator>
<dc:creator>Qingyong Fan</dc:creator>
<dc:creator>Shuzhi Lv</dc:creator>
<dc:creator>Dongliang Wu</dc:creator>
<dc:creator>Qiming Dai</dc:creator>
<dc:creator>Fuyu Qiu</dc:creator>
<dc:creator>Han Cai</dc:creator>
<dc:creator>Yu-Jie Zhou</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Netrod™ six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial</dc:title>
<dc:identifier>pmid:39431289</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae703</dc:identifier>
</item>
<item>
<title>Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429196/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Together, our studies revealed the mechanistic underpinnings of ALK1 signaling in regulating the endothelial phenotype and provided possibilities for new therapeutic strategies in hemorrhagic telangiectasia type 2.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070925. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Arteriovenous malformations (AVMs) are characteristic of hereditary hemorrhagic telangiectasia. Loss-of-function mutations in the activin receptor-like kinase 1 (<i>Alk1</i>) are linked to hemorrhagic telangiectasia type 2.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Endothelial-specific deletion of <i>Alk1,</i> endothelial lineage tracing, transcriptomics of single-cell analysis, and electron microscopy were performed to examine the vascular phenotype and characteristics of ALK1-deficient endothelial cells (ECs) after EC-specific <i>Alk1</i> deletion. Ischemia assays were used to examine the cell capacity for vascular malformation. Connectivity Map with transcriptomic analysis was applied to identify chemical compounds. Specific methods for arteriovenous malformations, such as micro-computed tomography, with other molecular and cell biological tools were also performed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We performed endothelial-specific deletion of <i>Alk1</i> in mice and found severe arteriovenous malformations and vascular leakage. The transcriptomics of single-cell analysis revealed a new distinctive cell cluster formed after <i>Alk1</i> deletion where the cells coexpressed arterial and lymphatic endothelial markers. The analysis projected that these cells potentially originated from arterial ECs after <i>Alk1</i> deletion. This new population was referred to as arterial-lymphatic-like ECs according to its cellular markers, and its appearance was validated in the pulmonary small arteries after <i>Alk1</i> deletion. Transplantation of these cells caused vascular malformations. Endothelial lineage tracing confirmed that these new arterial-lymphatic-like ECs were derived from ALK1 depleted ECs, potentially arterial ECs. We discovered that SOX17 (SRY-box transcription factor 17) induction was responsible for the derivation of these arterial-lymphatic-like ECs. We showed that direct binding of MDM2 (mouse double minute 2) was required for Sox17 to execute this activity. Inhibition of MDM2 reduced the arteriovenous malformations in the mouse model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Together, our studies revealed the mechanistic underpinnings of ALK1 signaling in regulating the endothelial phenotype and provided possibilities for new therapeutic strategies in hemorrhagic telangiectasia type 2.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429196/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39429196</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070925>10.1161/CIRCULATIONAHA.124.070925</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429196</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yang Yang</dc:creator>
<dc:creator>Xiuju Wu</dc:creator>
<dc:creator>Yan Zhao</dc:creator>
<dc:creator>Daoqin Zhang</dc:creator>
<dc:creator>Li Zhang</dc:creator>
<dc:creator>Xinjiang Cai</dc:creator>
<dc:creator>Jaden Ji</dc:creator>
<dc:creator>Zheng Jing</dc:creator>
<dc:creator>Kristina I Boström</dc:creator>
<dc:creator>Yucheng Yao</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Arterial-Lymphatic-Like Endothelial Cells Appear in Hereditary Hemorrhagic Telangiectasia 2 and Contribute to Vascular Leakage and Arteriovenous Malformations</dc:title>
<dc:identifier>pmid:39429196</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070925</dc:identifier>
</item>
<item>
<title>Cytotoxic T-Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429148/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 21. doi: 10.1161/CIRCRESAHA.124.325183. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429148/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39429148</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325183>10.1161/CIRCRESAHA.124.325183</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429148</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Maurits A Sikking</dc:creator>
<dc:creator>Daniel Harding</dc:creator>
<dc:creator>Michiel T H M Henkens</dc:creator>
<dc:creator>Sophie L V M Stroeks</dc:creator>
<dc:creator>Max F G H M Venner</dc:creator>
<dc:creator>Bastien Nihant</dc:creator>
<dc:creator>Rick E W van Leeuwen</dc:creator>
<dc:creator>Silvia Fanti</dc:creator>
<dc:creator>Xiaofei Li</dc:creator>
<dc:creator>Pieter van Paassen</dc:creator>
<dc:creator>Christian Knackstedt</dc:creator>
<dc:creator>Hans-Peter Brunner-la Rocca</dc:creator>
<dc:creator>Vanessa P M van Empel</dc:creator>
<dc:creator>Job A J Verdonschot</dc:creator>
<dc:creator>Federica M Marelli-Berg</dc:creator>
<dc:creator>Stephane R B Heymans</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cytotoxic T-Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy</dc:title>
<dc:identifier>pmid:39429148</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325183</dc:identifier>
</item>
<item>
<title>Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429145/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with heart failure and preserved ejection fraction, even modest baseline impairment of cognitive function was associated with worse outcomes, including death. A decline in MMSE score during follow-up was a strong predictor of mortality, independent of other prognostic variables.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.124.070553. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We analyzed cognitive function, using the Mini-Mental State Examination (MMSE), in patients with heart failure and preserved ejection fraction enrolled in a prespecified substudy of the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction). Logistic regression analyses were performed to determine the variables associated with lower MMSE scores at baseline and postbaseline decline in MMSE scores at 48 weeks. Cox proportional hazards regression and semiparametric proportional rates models were used to examine the risk of clinical outcomes related to baseline MMSE scores, and decline in MMSE scores during follow-up, adjusted for prognostic variables including NT-proBNP (N-terminal pro-B-type natriuretic peptide).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At baseline, cognitive function was normal (MMSE score 28-30) in 1809 of 2895 patients (62.5%), borderline (score 24-27) in 794 (27.4%), and impaired (score &lt;24) in 292 (10.1%). Variables associated with both a lower MMSE score at baseline and a decline in score from baseline included older age, a history of stroke or transient ischemia attack, and lower serum albumin. Compared with those with baseline MMSE scores of 28 to 30, patients in the lower MMSE score categories had a stepwise increase in the risk of the composite of time to first HF hospitalization or cardiovascular death, with an adjusted hazard ratio of 1.27 (95% CI, 1.06-1.53) for those with scores of 24 to 27 and 1.58 (95% CI, 1.21-2.06) for those with scores &lt;24, respectively. These associations were also found for the individual components of the composite and all-cause death. Likewise, cognitive impairment was associated with a 50% higher risk of total (first and repeat) heart failure hospitalizations and cardiovascular deaths. Examining the change in MMSE score from baseline, a decrease in MMSE score during follow-up was associated with a higher risk of death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with heart failure and preserved ejection fraction, even modest baseline impairment of cognitive function was associated with worse outcomes, including death. A decline in MMSE score during follow-up was a strong predictor of mortality, independent of other prognostic variables.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429145/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39429145</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070553>10.1161/CIRCULATIONAHA.124.070553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429145</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Li Shen</dc:creator>
<dc:creator>Pooja Dewan</dc:creator>
<dc:creator>João Pedro Ferreira</dc:creator>
<dc:creator>Jonathan W Cunningham</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Inder S Anand</dc:creator>
<dc:creator>Alvin Chandra</dc:creator>
<dc:creator>Lu-May Chiang</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Jianjian Gong</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Martin P Lefkowitz</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Felipe Martinez</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Margaret M Redfield</dc:creator>
<dc:creator>Jean L Rouleau</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF</dc:title>
<dc:identifier>pmid:39429145</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070553</dc:identifier>
</item>
<item>
<title>Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Increased systemic or local S1P levels lead to increased valvular calcification. S1PR2 antagonists and SphK1 inhibitors may offer feasible pharmacological approaches to human AVD in prophylactic, disease-modifying or relapse-preventing manners.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 21. doi: 10.1161/CIRCULATIONAHA.123.067270. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Aortic valve disease (AVD) is associated with high mortality and morbidity. To date, there is no pharmacological therapy available to prevent AVD progression. Because valve calcification is the hallmark of AVD and S1P (sphingosine-1-phosphate) plays an important role in osteogenic signaling, we examined the role of S1P signaling in aortic stenosis disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: AVD progression and its consequences for cardiac function were examined in a murine wire injury-induced AVD model with and without pharmacological and genetic modulation of S1P production, degradation, and receptor signaling. S1P was measured by LC-MS. Calcification of valvular interstitial cells and their response to biomechanical stress were analyzed in the context of S1P signaling. Human explanted aortic valves from patients undergoing aortic valve replacement and cardiovascular magnetic resonance imaging were analyzed for S1P by LC-MS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Raising S1P concentrations in mice with injury-induced AVD by pharmacological inhibition of its sole degrading enzyme S1P lyase vastly enhanced AVD progression and impaired cardiac function resembling human disease. In contrast, low S1P levels caused by SphK1 (sphingosine kinase 1) deficiency potently attenuated AVD progression. We found S1P/S1PR2 (S1P receptor 2) signaling to be responsible for the adverse S1P effect because S1PR2-deficient mice were protected against AVD progression and its deterioration by high S1P. It is important to note that pharmacological S1PR2 inhibition administered after wire injury successfully prevented AVD development. Mechanistically, biomechanical stretch stimulated S1P production by SphK1 in human valvular interstitial cells as measured by C17-S1P generation, whereas S1P/S1PR2 signaling induced their osteoblastic differentiation and calcification through osteogenic RUNX2/OPG signaling and the GSK3β-Wnt-β-catenin pathway. In patients with AVD, stenotic valves exposed to high wall shear stress had higher S1P content and increased SphK1 expression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Increased systemic or local S1P levels lead to increased valvular calcification. S1PR2 antagonists and SphK1 inhibitors may offer feasible pharmacological approaches to human AVD in prophylactic, disease-modifying or relapse-preventing manners.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39429140</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067270>10.1161/CIRCULATIONAHA.123.067270</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429140</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marcel Benkhoff</dc:creator>
<dc:creator>Maike Barcik</dc:creator>
<dc:creator>Philipp Mourikis</dc:creator>
<dc:creator>Jana Dahlmanns</dc:creator>
<dc:creator>Paulina Kahmann</dc:creator>
<dc:creator>Philipp Wollnitzke</dc:creator>
<dc:creator>Moritz Hering</dc:creator>
<dc:creator>Tim Huckenbeck</dc:creator>
<dc:creator>Julia Hoppe</dc:creator>
<dc:creator>Nina Semleit</dc:creator>
<dc:creator>Jennifer Deister-Jonas</dc:creator>
<dc:creator>Saif Zako</dc:creator>
<dc:creator>Jasmin Seel</dc:creator>
<dc:creator>Cristina Coman</dc:creator>
<dc:creator>Mareike Barth</dc:creator>
<dc:creator>Mareike Cramer</dc:creator>
<dc:creator>Carolin Helten</dc:creator>
<dc:creator>Laura Wildeis</dc:creator>
<dc:creator>Hao Hu</dc:creator>
<dc:creator>Gabrielle Al-Kassis</dc:creator>
<dc:creator>Daniel Metzen</dc:creator>
<dc:creator>Julia Hesse</dc:creator>
<dc:creator>Jessica Weber</dc:creator>
<dc:creator>Lisa Dannenberg</dc:creator>
<dc:creator>Payam Akhyari</dc:creator>
<dc:creator>Artur Lichtenberg</dc:creator>
<dc:creator>Christine Quast</dc:creator>
<dc:creator>Norbert Gerdes</dc:creator>
<dc:creator>Tobias Zeus</dc:creator>
<dc:creator>Oliver Borst</dc:creator>
<dc:creator>Malte Kelm</dc:creator>
<dc:creator>Tobias Petzold</dc:creator>
<dc:creator>Robert Ahrends</dc:creator>
<dc:creator>Bodo Levkau</dc:creator>
<dc:creator>Amin Polzin</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Targeting Sphingosine-1-Phosphate Signaling to Prevent the Progression of Aortic Valve Disease</dc:title>
<dc:identifier>pmid:39429140</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067270</dc:identifier>
</item>
<item>
<title>Prognosis after switching to electronic cigarettes following percutaneous coronary intervention: a Korean nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39429032/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among smokers who underwent PCI for coronary artery disease, switching to E-cigarette use (particularly complete transition) or quitting smoking was associated with reduced MACE risk than with continued combustible cigarette use.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae705. doi: 10.1093/eurheartj/ehae705. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Despite the increasing popularity of electronic cigarettes (E-cigarettes), the prognostic impact of switching to E-cigarettes in smokers with coronary artery disease who have undergone percutaneous coronary intervention (PCI) remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a nationwide cohort from the Korean National Health Insurance database, 17 973 adults (≥20 years) identified as smokers (based on a health screening examination within 3 years before PCI) who underwent health screening within 3 years after PCI were enrolled to determine changes in smoking habits. Patients were classified as continued combustible cigarette users, successful quitters, or switchers to E-cigarettes. The group switching to E-cigarettes was further divided into dual users (using both combustible and E-cigarettes) and those exclusively using E-cigarettes. Primary outcomes included major adverse cardiac events (MACEs), a composite of all-cause death, spontaneous myocardial infarction, and repeat revascularization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the total population, 8951 patients (49.8%) continued using combustible cigarettes, 1694 (9.4%) were switched to E-cigarettes, and 7328 (40.7%) successfully quit smoking after PCI. During a median follow-up of 2.4 years, the cumulative incidence of MACE was lower among E-cigarette switchers (10%) or quitters (13.4%) than among continued combustible cigarette users (17%). When continued combustible cigarette users were used as the reference, the multivariable-adjusted hazard ratios with 95% confidence intervals for MACE were 0.82 (0.69-0.98) for switchers to E-cigarettes and 0.87 (0.79-0.96) for successful quitters. Compared with dual users, entirely switching to E-cigarettes was associated with a significantly lower MACE risk (hazard ratio 0.71; 95% confidence interval 0.51-0.99).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among smokers who underwent PCI for coronary artery disease, switching to E-cigarette use (particularly complete transition) or quitting smoking was associated with reduced MACE risk than with continued combustible cigarette use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT06338761.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39429032/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39429032</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae705>10.1093/eurheartj/ehae705</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39429032</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Danbee Kang</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:creator>Hyunsoo Kim</dc:creator>
<dc:creator>Hyejeong Park</dc:creator>
<dc:creator>Jihye Heo</dc:creator>
<dc:creator>Taek Kyu Park</dc:creator>
<dc:creator>Joo Myung Lee</dc:creator>
<dc:creator>Juhee Cho</dc:creator>
<dc:creator>Jeong Hoon Yang</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Seung-Hyuk Choi</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Prognosis after switching to electronic cigarettes following percutaneous coronary intervention: a Korean nationwide study</dc:title>
<dc:identifier>pmid:39429032</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae705</dc:identifier>
</item>
<item>
<title>Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428997/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The risk of major clinical outcomes did not differ between individuals with and without AF-related symptoms. Asymptomatic patients had a greater hazard of progression to permanent AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae694. doi: 10.1093/eurheartj/ehae694. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Current guidelines suggest that asymptomatic atrial fibrillation (AF) is independently associated with increased risks of stroke and mortality compared with symptomatic AF. Considering that recent investigations have provided conflicting results, the present study aimed to evaluate the association between symptom status and clinical outcomes in patients with AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Medline, Cochrane Library, and Scopus were searched until 25 March 2024. Triple-independent study selection, data extraction and quality assessment were performed. Evidence was pooled using random-effects meta-analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Thirty-six studies (217 850 participants) were included. Based on the frequentist analysis, symptomatic individuals had no significant difference in the risk of all-cause mortality [hazard ratio (HR) .97, 95% confidence interval (CI) .80-1.17], cardiovascular mortality (HR 1.04, 95% CI .72-1.49), thromboembolism (HR 1.06, 95% CI .87-1.28), stroke (HR 1.06, 95% CI .84-1.34), hospitalization (HR 1.34, 95% CI .89-2.02), and myocardial infarction (HR .98, 95% CI .70-1.36), compared to the asymptomatic group. Symptomatic patients had a 33% increased risk of new-onset heart failure (HR 1.33, 95% CI 1.19-1.49) and a 30% lower risk of progression to permanent AF (HR .70, 95% CI .54-.89). The Bayesian analysis yielded comparable results, yet the association between symptom status and new-onset heart failure was not significant (HR 1.27, 95% credible interval .76-1.93; Bayes factor = 1.2). Symptomatic patients had higher odds of receiving antiarrhythmic drugs (odds ratio [OR] 1.64, 95% CI 1.33-2.03) and ablation therapy (OR 1.47, 95% CI 1.06-2.05) compared to asymptomatic cases.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The risk of major clinical outcomes did not differ between individuals with and without AF-related symptoms. Asymptomatic patients had a greater hazard of progression to permanent AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428997/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39428997</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae694>10.1093/eurheartj/ehae694</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428997</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Paschalis Karakasis</dc:creator>
<dc:creator>Konstantinos Pamporis</dc:creator>
<dc:creator>Konstantinos C Siontis</dc:creator>
<dc:creator>Panagiotis Theofilis</dc:creator>
<dc:creator>Athanasios Samaras</dc:creator>
<dc:creator>Dimitrios Patoulias</dc:creator>
<dc:creator>Panagiotis Stachteas</dc:creator>
<dc:creator>Efstratios Karagiannidis</dc:creator>
<dc:creator>George Stavropoulos</dc:creator>
<dc:creator>Apostolos Tzikas</dc:creator>
<dc:creator>George Kassimis</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>Theodoros Karamitsos</dc:creator>
<dc:creator>Demosthenes G Katritsis</dc:creator>
<dc:creator>Nikolaos Fragakis</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Major clinical outcomes in symptomatic vs. asymptomatic atrial fibrillation: a meta-analysis</dc:title>
<dc:identifier>pmid:39428997</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae694</dc:identifier>
</item>
<item>
<title>Changing of the guard at the European Society of Cardiology's prevention journal</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428580/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae642. doi: 10.1093/eurheartj/ehae642. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428580/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39428580</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae642>10.1093/eurheartj/ehae642</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428580</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jennifer Taylor</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Changing of the guard at the European Society of Cardiology's prevention journal</dc:title>
<dc:identifier>pmid:39428580</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae642</dc:identifier>
</item>
<item>
<title>Peerless performance: celebrating the backstage champions of scientific publishing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae662. doi: 10.1093/eurheartj/ehae662. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39428576</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae662>10.1093/eurheartj/ehae662</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428576</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Peerless performance: celebrating the backstage champions of scientific publishing</dc:title>
<dc:identifier>pmid:39428576</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae662</dc:identifier>
</item>
<item>
<title>Leaders in cardiology: Anna Strömberg</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428569/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21:ehae629. doi: 10.1093/eurheartj/ehae629. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428569/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39428569</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae629>10.1093/eurheartj/ehae629</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428569</guid>
<pubDate>Mon, 21 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Judith Ozkan</dc:creator>
<dc:date>2024-10-21</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leaders in cardiology: Anna Strömberg</dc:title>
<dc:identifier>pmid:39428569</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae629</dc:identifier>
</item>
<item>
<title>Innovative approaches to the management of recurrent atrial fibrillation, aortic dilation, and Brugada syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39428116/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Oct 21;45(40):4245-4248. doi: 10.1093/eurheartj/ehae702.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39428116/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39428116</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae702>10.1093/eurheartj/ehae702</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39428116</guid>
<pubDate>Sun, 20 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-10-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Innovative approaches to the management of recurrent atrial fibrillation, aortic dilation, and Brugada syndrome</dc:title>
<dc:identifier>pmid:39428116</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae702</dc:identifier>
</item>
<item>
<title>A two-front nutrient supply environment fuels small intestinal physiology through differential regulation of nutrient absorption and host defense</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39427662/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>The small intestine contains a two-front nutrient supply environment created by luminal dietary and microbial metabolites (enteral side) and systemic metabolites from the host (serosal side). Yet, it is unknown how each side contributes differentially to the small intestinal physiology. Here, we generated a comprehensive, high-resolution map of the small intestinal two-front nutrient supply environment. Using in vivo tracing of macronutrients and spatial metabolomics, we visualized the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 19:S0092-8674(24)00903-6. doi: 10.1016/j.cell.2024.08.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The small intestine contains a two-front nutrient supply environment created by luminal dietary and microbial metabolites (enteral side) and systemic metabolites from the host (serosal side). Yet, it is unknown how each side contributes differentially to the small intestinal physiology. Here, we generated a comprehensive, high-resolution map of the small intestinal two-front nutrient supply environment. Using in vivo tracing of macronutrients and spatial metabolomics, we visualized the spatiotemporal dynamics and cell-type tropism in nutrient absorption and the region-specific metabolic heterogeneity within the villi. Specifically, glutamine from the enteral side fuels goblet cells to support mucus production, and the serosal side loosens the epithelial barrier by calibrating fungal metabolites. Disorganized feeding patterns, akin to the human lifestyle of skipping breakfast, increase the risk of metabolic diseases by inducing epithelial memory of lipid absorption. This study improves our understanding of how the small intestine is spatiotemporally regulated by its unique nutritional environment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39427662/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39427662</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.012>10.1016/j.cell.2024.08.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39427662</guid>
<pubDate>Sun, 20 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Jian Zhang</dc:creator>
<dc:creator>Ruonan Tian</dc:creator>
<dc:creator>Jia Liu</dc:creator>
<dc:creator>Jie Yuan</dc:creator>
<dc:creator>Siwen Zhang</dc:creator>
<dc:creator>Zhexu Chi</dc:creator>
<dc:creator>Weiwei Yu</dc:creator>
<dc:creator>Qianzhou Yu</dc:creator>
<dc:creator>Zhen Wang</dc:creator>
<dc:creator>Sheng Chen</dc:creator>
<dc:creator>Mobai Li</dc:creator>
<dc:creator>Dehang Yang</dc:creator>
<dc:creator>Tianyi Hu</dc:creator>
<dc:creator>Qiqi Deng</dc:creator>
<dc:creator>Xiaoyang Lu</dc:creator>
<dc:creator>Yidong Yang</dc:creator>
<dc:creator>Rongbin Zhou</dc:creator>
<dc:creator>Xue Zhang</dc:creator>
<dc:creator>Wanlu Liu</dc:creator>
<dc:creator>Di Wang</dc:creator>
<dc:date>2024-10-20</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A two-front nutrient supply environment fuels small intestinal physiology through differential regulation of nutrient absorption and host defense</dc:title>
<dc:identifier>pmid:39427662</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.012</dc:identifier>
</item>
<item>
<title>Light-induced targeting enables proteomics on endogenous condensates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39426378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>Endogenous condensates with transient constituents are notoriously difficult to study with common biological assays like mass spectrometry and other proteomics profiling. Here, we report a method for light-induced targeting of endogenous condensates (LiTEC) in living cells. LiTEC combines the identification of molecular zip codes that target the endogenous condensates with optogenetics to enable controlled and reversible partitioning of an arbitrary cargo, such as enzymes commonly used in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 15:S0092-8674(24)01140-1. doi: 10.1016/j.cell.2024.09.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Endogenous condensates with transient constituents are notoriously difficult to study with common biological assays like mass spectrometry and other proteomics profiling. Here, we report a method for light-induced targeting of endogenous condensates (LiTEC) in living cells. LiTEC combines the identification of molecular zip codes that target the endogenous condensates with optogenetics to enable controlled and reversible partitioning of an arbitrary cargo, such as enzymes commonly used in proteomics, into the condensate in a blue light-dependent manner. We demonstrate a proof of concept by combining LiTEC with proximity-based biotinylation (BioID) and uncover putative components of transcriptional condensates in mouse embryonic stem cells. Our approach opens the road to genome-wide functional studies of endogenous condensates.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39426378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39426378</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.040>10.1016/j.cell.2024.09.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39426378</guid>
<pubDate>Sat, 19 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Choongman Lee</dc:creator>
<dc:creator>Andrea Quintana</dc:creator>
<dc:creator>Ida Suppanz</dc:creator>
<dc:creator>Alejandro Gomez-Auli</dc:creator>
<dc:creator>Gerhard Mittler</dc:creator>
<dc:creator>Ibrahim I Cissé</dc:creator>
<dc:date>2024-10-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Light-induced targeting enables proteomics on endogenous condensates</dc:title>
<dc:identifier>pmid:39426378</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.040</dc:identifier>
</item>
<item>
<title>From periphery to center stage: 50 years of advancements in innate immunity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39426377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 18:S0092-8674(24)01189-9. doi: 10.1016/j.cell.2024.10.013. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39426377/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39426377</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.013>10.1016/j.cell.2024.10.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39426377</guid>
<pubDate>Sat, 19 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Susan Carpenter</dc:creator>
<dc:creator>Luke A J O'Neill</dc:creator>
<dc:date>2024-10-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>From periphery to center stage: 50 years of advancements in innate immunity</dc:title>
<dc:identifier>pmid:39426377</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.013</dc:identifier>
</item>
<item>
<title>RNA G-quadruplexes form scaffolds that promote neuropathological α-synuclein aggregation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39426376/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241022001409&amp;v=2.18.0.post9+e462414
      <description>Synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, are triggered by α-synuclein aggregation, triggering progressive neurodegeneration. However, the intracellular α-synuclein aggregation mechanism remains unclear. Herein, we demonstrate that RNA G-quadruplex assembly forms scaffolds for α-synuclein aggregation, contributing to neurodegeneration. Purified α-synuclein binds RNA G-quadruplexes directly through the N terminus. RNA G-quadruplexes...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 14:S0092-8674(24)01134-6. doi: 10.1016/j.cell.2024.09.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, are triggered by α-synuclein aggregation, triggering progressive neurodegeneration. However, the intracellular α-synuclein aggregation mechanism remains unclear. Herein, we demonstrate that RNA G-quadruplex assembly forms scaffolds for α-synuclein aggregation, contributing to neurodegeneration. Purified α-synuclein binds RNA G-quadruplexes directly through the N terminus. RNA G-quadruplexes undergo Ca<sup>2+</sup>-induced phase separation and assembly, accelerating α-synuclein sol-gel phase transition. In α-synuclein preformed fibril-treated neurons, RNA G-quadruplex assembly comprising synaptic mRNAs co-aggregates with α-synuclein upon excess cytoplasmic Ca<sup>2+</sup> influx, eliciting synaptic dysfunction. Forced RNA G-quadruplex assembly using an optogenetic approach evokes α-synuclein aggregation, causing neuronal dysfunction and neurodegeneration. The administration of 5-aminolevulinic acid, a protoporphyrin IX prodrug, prevents RNA G-quadruplex phase separation, thereby attenuating α-synuclein aggregation, neurodegeneration, and progressive motor deficits in α-synuclein preformed fibril-injected synucleinopathic mice. Therefore, Ca<sup>2+</sup> influx-induced RNA G-quadruplex assembly accelerates α-synuclein phase transition and aggregation, potentially contributing to synucleinopathies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39426376/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241022001409&v=2.18.0.post9+e462414">39426376</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.037>10.1016/j.cell.2024.09.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39426376</guid>
<pubDate>Sat, 19 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Kazuya Matsuo</dc:creator>
<dc:creator>Sefan Asamitsu</dc:creator>
<dc:creator>Kohei Maeda</dc:creator>
<dc:creator>Hiroyoshi Suzuki</dc:creator>
<dc:creator>Kosuke Kawakubo</dc:creator>
<dc:creator>Ginji Komiya</dc:creator>
<dc:creator>Kenta Kudo</dc:creator>
<dc:creator>Yusuke Sakai</dc:creator>
<dc:creator>Karin Hori</dc:creator>
<dc:creator>Susumu Ikenoshita</dc:creator>
<dc:creator>Shingo Usuki</dc:creator>
<dc:creator>Shiori Funahashi</dc:creator>
<dc:creator>Hideki Oizumi</dc:creator>
<dc:creator>Atsushi Takeda</dc:creator>
<dc:creator>Yasushi Kawata</dc:creator>
<dc:creator>Tomohiro Mizobata</dc:creator>
<dc:creator>Norifumi Shioda</dc:creator>
<dc:creator>Yasushi Yabuki</dc:creator>
<dc:date>2024-10-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>RNA G-quadruplexes form scaffolds that promote neuropathological α-synuclein aggregation</dc:title>
<dc:identifier>pmid:39426376</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.037</dc:identifier>
</item>





























</channel>
</rss>